Artery Blocking Articles & Analysis
16 news found
Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young woman that had destroyed her leg veins, the best options for the bypass procedure. ...
Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...
ArterioSorb is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaffold (BRS, stent), to ...
About Chronic Refractory Angina In the United States, coronary artery disease is a leading cause of death and disability. Chronic angina pectoris occurs when the heart muscle does not receive sufficient oxygen resulting in chest pain. This is usually due to atherosclerotic plaques that block the coronary arteries. Refractory angina is a growing ...
About Chronic Refractory Angina In the United States, coronary artery disease is a leading cause of death and disability. Chronic angina pectoris occurs when the heart muscle does not receive sufficient oxygen resulting in chest pain. This is usually due to atherosclerotic plaques that block the coronary arteries. Refractory angina is a growing ...
During CABG, a healthy artery or vein from the body is connected, or grafted, to the blocked coronary artery. The grafted artery or vein bypasses the blocked portion of the coronary artery. This creates a new passage, and oxygen-rich blood is routed around the blockage to the heart muscle. ...
Additional country principal investigators for the BIOADAPTOR RCT are: Holger Nef, MD, Universitätsklinikum Giessen, Germany Stefan Verheye, MD, PhD, Antwerp Cardiovascular Centre/ZNA Middleheim, Belgium “Drug-eluting stents have been a good technology for opening and supporting blocked coronary arteries for many years; however, published ...
Over six months, the polymer coating dissolves, uncaging the bioadaptor and freeing the artery to move with the natural expansion and contraction of the artery, unlike DES. ...
A catheter-based device is inserted via the femoral artery, blocking blood flow to the lower extremities within a minute and rerouting it to vital organs. ...
The system is designed to monitor compromised tissue in conditions such as peripheral artery disease (PAD) and critical limb ischemia (CLI). Both conditions result from a narrowing of blood vessels and reduced blood flow to the lower limbs. ...
“We have successfully demonstrated that a physician can use a robotic system in a manner necessary to open a blocked artery despite being 3,000 miles away. This represents the next step in achieving our ultimate goal of providing remote cardiovascular care to patients suffering a heart attack or stroke who do not currently have access to potentially ...
Mar. 19, 2019 --(BUSINESS WIRE)--Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and ...
All of these important advancements have underscored that, as in the treatment of acute myocardial infarctions, improved mechanical solutions to physically open the blocked brain artery will continue to offer clear advantages for improved patient outcomes,” said Imperative Care co-founder L. ...
The company will initially market the system for monitoring tissue oxygen in the treatment of peripheral artery disease (PAD). With an annual economic burden of more than $74 billion dollars in the United States alone, PAD affects 202 million people worldwide. ...
Pieces of the clot may travel to the lungs blocking branches of the pulmonary artery. Symptoms of Lemierre’s syndrome may include sore throat, fever and general weakness. ...